Resectable Pancreatic AdenocarcinomaSCC-miRPanCaNCT05275075
Identify microRNAs in Cachexia in Pancreatic Carcinoma
An observational study of Resectable Pancreatic Adenocarcinoma, run by University of Oklahoma at 1 site in United States.
Trial summary
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Resectable Pancreatic Adenocarcinoma
- What is being tested?
- Pancreatic cancer microRNA and messenger RNA expression.
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Dec 2022to 3 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population is inclusive of all races, ethnicities, and gender. Enrollment into the study is restricted to Stephenson Cancer Center site, part of the University Oklahoma Health Sciences Center.
Who may be able to join
- Male or female patient, who is ≥ 18 years old at the time of informed consent.
- Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
- Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
- Ability to provide written informed consent and HIPAA authorization.
Who cannot join
- Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
- Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
Trial locations and contacts
1 site in 1 country.
United States1 site
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117
About this study
Official title: Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Read the detailed description
This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospective arm, will enroll a total of 100 eligible volunteers at the OU-SCC. The demographic and medical data from the retrospective and prospective arms will be combined (1495 patients) to ascertain any racial disparities in pancreatic cancer patients with cachexia. Perspective volunteers at the OU-SCC will undergo routine tests to determine if their cancer is operable. Pancreatic tumors will be removed from the eligible patients, as part of their normal standard of care and will be examined for genes that may be related to unexplained muscle loss and compared to tumor tissue from other patients with pancreatic cancer. An optional hand strength exam, and standing on a scale that measures weight, muscle, and body fat will be available to OU-SCC patients.
- Conditions
- Resectable Pancreatic Adenocarcinoma
- Being tested
- Pancreatic cancer microRNA and messenger RNA expression.
- Keywords
- pancreatic cancer, cachexia, microRNA, mRNA, PDAC
- Medical subject headings
- Pancreatic Neoplasms, Cachexia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pancreatic cancer microRNA and messenger RNA expression.Other
Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
| Study group | Role | What they receive |
|---|---|---|
| Pancreatic Cancer Cohort | All eligible adenocarcinoma pancreatic cancer patients with operable cancer. Receives: Other: Pancreatic cancer microRNA and messenger RNA expression. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of African American pancreatic cancer patients with weight loss and cachexia.
Evaluate weight loss and the markers of cachexia, albumin and psoas cross-sectional area, to see if African Americans with pancreatic cancer patients experience Grade I-IV cachexia at a higher frequency than other racial groups.
Measured: 1 - 12 months
Secondary outcomes (2)
Differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery.
Assess fold-change expression differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery.
Measured: 1 - 12 months
Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.
Assess fold-change expression differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.
Measured: 1 - 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2022
- Study start7 Dec 2022
- Primary completion3 Apr 2026
- Study completion3 Apr 2026
Why it stopped: Translational scientist left university
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Resectable Pancreatic AdenocarcinomaStudies of the same condition, open and under way.
- More trials run by University of OklahomaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oklahoma
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ajay Jain, MD, Principal investigator, University of Oklahoma Stephenson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05275075
- Sponsor's protocol ID
- OU-SCC-MIRPANCA
- Acronym
- SCC-miRPanCa
- Status last verified
- May 2026
- First submitted
- 2 Mar 2022
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma
- ClinicalTrials.gov ID
- NCT05275075
- Acronym / sponsor ID
- SCC-miRPanCa / OU-SCC-MIRPANCA
- Conditions
- Resectable Pancreatic Adenocarcinoma
- Keywords
- pancreatic cancer, cachexia, microRNA, mRNA, PDAC
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Translational scientist left university
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University of OklahomaUniversity, hospital or other
- Study start
- 7 Dec 2022 (actual)
- Primary completion
- 3 Apr 2026 (actual)
- Study completion
- 3 Apr 2026 (actual)
- First posted
- 11 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Detailed description
This research study will retrospectively examine 1395 patients from the University of Alabama and the University of Oklahoma Stephenson Cancer Center (OU-SCC) pancreatic cancer cohorts. The prospective arm, will enroll a total of 100 eligible volunteers at the OU-SCC. The demographic and medical data from the retrospective and prospective arms will be combined (1495 patients) to ascertain any racial disparities in pancreatic cancer patients with cachexia. Perspective volunteers at the OU-SCC will undergo routine tests to determine if their cancer is operable. Pancreatic tumors will be removed from the eligible patients, as part of their normal standard of care and will be examined for genes that may be related to unexplained muscle loss and compared to tumor tissue from other patients with pancreatic cancer. An optional hand strength exam, and standing on a scale that measures weight, muscle, and body fat will be available to OU-SCC patients.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pancreatic Cancer Cohort | – | Other: Pancreatic cancer microRNA and messenger RNA expression.All eligible adenocarcinoma pancreatic cancer patients with operable cancer. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population is inclusive of all races, ethnicities, and gender. Enrollment into the study is restricted to Stephenson Cancer Center site, part of the University Oklahoma Health Sciences Center.
Key inclusion criteria (4 listed)
- Male or female patient, who is ≥ 18 years old at the time of informed consent.
- Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
- Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
- Ability to provide written informed consent and HIPAA authorization.
Key exclusion criteria (2 listed)
- Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
- Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pancreatic cancer microRNA and messenger RNA expression.Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss. | Other | Pancreatic Cancer Cohort |
Primary outcome
Proportion of African American pancreatic cancer patients with weight loss and cachexia.
Time frame: 1 - 12 months
Evaluate weight loss and the markers of cachexia, albumin and psoas cross-sectional area, to see if African Americans with pancreatic cancer patients experience Grade I-IV cachexia at a higher frequency than other racial groups.
2 secondary outcomes
Differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery.
Time frame: 1 - 12 months
Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.
Time frame: 1 - 12 months
Results and safety
The study was stopped early (reason given: Translational scientist left university). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Resectable Pancreatic Adenocarcinoma
RecruitingPhase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma
RecruitingPhase 2
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Not yet recruitingPhase 1/2
A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 1/2
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
RecruitingPhase 1
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ajay Jain, MD principal investigator
University of Oklahoma Stephenson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Resectable Pancreatic Adenocarcinoma, run by University of Oklahoma at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Translational scientist left university). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of African American pancreatic cancer patients with weight loss and cachexia. (time frame: 1 - 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.